Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Leuk Lymphoma. 2020 Apr 7;61(8):1784–1796. doi: 10.1080/10428194.2020.1747068

Fig. 2.

Fig. 2.

The authors’ preferred treatment strategy for Burkitt lymphoma according to risk group and baseline CNS involvement status.

ARAC: cytarabine; CNS: central nervous system; IT: intrathecal; LDH: lactate dehydrogenase; MTX: methotrexate; PET: position emission tomography; TLS: tumor lysis syndrome